Gresham K - Search Results

1

A peptide of the N terminus of GRK5 attenuates pressure-overload hypertrophy and heart failure.

Coleman RC, Eguchi A, Lieu M, Roy R, Barr EW, Ibetti J, Lucchese AM, Peluzzo AM, Gresham K, Chuprun JK, Koch WJ. Coleman RC, et al. Among authors: gresham k. Sci Signal. 2021 Mar 30;14(676):eabb5968. doi: 10.1126/scisignal.abb5968. Sci Signal. 2021. PMID: 33785612 Free PMC article.

2

G protein-coupled receptor kinases as therapeutic targets in the heart.

Pfleger J, Gresham K, Koch WJ. Pfleger J, et al. Among authors: gresham k. Nat Rev Cardiol. 2019 Oct;16(10):612-622. doi: 10.1038/s41569-019-0220-3. Epub 2019 Jun 11. Nat Rev Cardiol. 2019. PMID: 31186538 Review.

3

GRK5 is a regulator of fibroblast activation and cardiac fibrosis.

Eguchi A, Coleman R, Gresham K, Gao E, Ibetti J, Chuprun JK, Koch WJ. Eguchi A, et al. Among authors: gresham k. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2012854118. doi: 10.1073/pnas.2012854118. Proc Natl Acad Sci U S A. 2021. PMID: 33500351 Free PMC article.

4

Alteration of myocardial GRK2 produces a global metabolic phenotype.

Woodall BP, Gresham KS, Woodall MA, Valenti MC, Cannavo A, Pfleger J, Chuprun JK, Drosatos K, Koch WJ. Woodall BP, et al. Among authors: gresham ks. JCI Insight. 2019 Apr 4;5(10):e123848. doi: 10.1172/jci.insight.123848. JCI Insight. 2019. PMID: 30946029 Free PMC article.

5

Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy.

Li J, Gresham KS, Mamidi R, Doh CY, Wan X, Deschenes I, Stelzer JE. Li J, et al. Among authors: gresham ks. Int J Cardiol. 2018 Dec 15;273:168-176. doi: 10.1016/j.ijcard.2018.09.073. Epub 2018 Sep 21. Int J Cardiol. 2018. PMID: 30279005 Free PMC article.

6

Cardiac myosin binding protein-C Ser³⁰² phosphorylation regulates cardiac β-adrenergic reserve.

Mamidi R, Gresham KS, Li J, Stelzer JE. Mamidi R, et al. Among authors: gresham ks. Sci Adv. 2017 Mar 10;3(3):e1602445. doi: 10.1126/sciadv.1602445. eCollection 2017 Mar. Sci Adv. 2017. PMID: 28345052 Free PMC article.

7

Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.

Mamidi R, Li J, Gresham KS, Verma S, Doh CY, Li A, Lal S, Dos Remedios CG, Stelzer JE. Mamidi R, et al. Among authors: gresham ks. Circ Heart Fail. 2017 Oct;10(10):e004257. doi: 10.1161/CIRCHEARTFAILURE.117.004257. Circ Heart Fail. 2017. PMID: 29030372 Free PMC article.

8

Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy.

Mamidi R, Li J, Gresham KS, Stelzer JE. Mamidi R, et al. Pflugers Arch. 2014 Feb;466(2):225-30. doi: 10.1007/s00424-013-1412-z. Epub 2013 Dec 6. Pflugers Arch. 2014. PMID: 24310821 Free PMC article.

9

The contribution of cardiac myosin binding protein-c Ser282 phosphorylation to the rate of force generation and in vivo cardiac contractility.

Gresham KS, Mamidi R, Stelzer JE. Gresham KS, et al. J Physiol. 2014 Sep 1;592(17):3747-65. doi: 10.1113/jphysiol.2014.276022. Epub 2014 Jun 20. J Physiol. 2014. PMID: 24951619 Free PMC article.

10

Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation.

Mamidi R, Gresham KS, Stelzer JE. Mamidi R, et al. Front Physiol. 2014 Dec 2;5:461. doi: 10.3389/fphys.2014.00461. eCollection 2014. Front Physiol. 2014. PMID: 25520665 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page